Effect of influenza vaccines against mismatched strains: A systematic review protocol

被引:8
|
作者
Tricco A.C. [1 ]
Chit A. [2 ,3 ]
Hallett D. [4 ]
Soobiah C. [1 ]
Meier G. [6 ]
Chen M. [1 ]
Tashkandi M. [5 ]
Bauch C. [7 ]
Loeb M. [8 ]
机构
[1] Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON
[2] GlaxoSmithKline, Mississauga, ON
[3] Faculty of Pharmacy, University of Toronto, Toronto, ON
[4] Institute of Medical Sciences, University of Toronto, Toronto, ON
[5] Applied Health Research Centre, St. Michael's Hospital, Toronto, ON
[6] North America Vaccines Division, GlaxoSmithKline, Philadelphia, PA
[7] Department of Mathematics and Statistics, University of Guelph, Guelph, ON
[8] McMaster University, Hamilton, ON
关键词
Antigenic variation; Cross protection; Influenza A virus; Influenza B virus; Protocol; Systematic review; Vaccines;
D O I
10.1186/2046-4053-1-35
中图分类号
学科分类号
摘要
Background: Influenza vaccines are most effective when the antigens in the vaccine match those of circulating influenza strains. The extent to which the vaccine is protective when circulating strains differ from vaccine antigens, or are mismatched, is uncertain. We propose to systematically review the cross-protection offered by influenza vaccines against circulating influenza A or B viruses that are not antigenically well-matched to vaccine strains.Methods/Design: This is a protocol for a systematic review and meta-analysis. Placebo-controlled randomized clinical trials (RCTs) reporting laboratory-confirmed influenza among healthy participants vaccinated with antigens of influenza strains that differed from those circulating will be included. The primary outcome is the incidence of laboratory-confirmed influenza (polymerase chain reaction (PCR) or viral culture). The secondary outcome is the incidence of laboratory-confirmed influenza through antibody assay (a less sensitive test than PCR or viral culture) alone or combined with PCR, and/ or viral culture. The review will be limited to RCTs written in English.We will search MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, previous influenza reviews, and the reference lists of included studies to identify potentially relevant RCTs. Two independent reviewers will conduct all levels of screening, data abstraction, and quality appraisal (using the Cochrane risk of bias tool).If appropriate, random effects meta-analysis of vaccine efficacy will be conducted in SAS (version 9.2) by calculating the relative risk. Vaccine efficacy will be calculated using the following formula: (1 - relative risk × 100). The results will be analyzed by type of vaccine (live attenuated, trivalent inactivated, or other). Subgroup analysis will include the effects of age (children, adults, older participants), and influenza A versus influenza B on the results. For influenza B we will also consider variable degrees of antigenic mismatch (lineage and drift mismatch).Discussion: Our results can be used by researchers and policy-makers to help predict the efficacy of influenza vaccines during mismatched influenza seasons. Furthermore, the review will be of interest to patients and clinicians to determine whether to get immunized or support immunization for a particular influenza season. © 2012 Tricco et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials
    Youhanna, John
    Tran, Vy
    Hyer, Randall
    Domnich, Alexander
    [J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (04)
  • [2] Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis
    Andrea C Tricco
    Ayman Chit
    Charlene Soobiah
    David Hallett
    Genevieve Meier
    Maggie H Chen
    Mariam Tashkandi
    Chris T Bauch
    Mark Loeb
    [J]. BMC Medicine, 11
  • [3] Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis
    Tricco, Andrea C.
    Chit, Ayman
    Soobiah, Charlene
    Hallett, David
    Meier, Genevieve
    Chen, Maggie H.
    Tashkandi, Mariam
    Bauch, Chris T.
    Loeb, Mark
    [J]. BMC MEDICINE, 2013, 11
  • [4] A systematic review of intradermal influenza vaccines
    Young, Flora
    Marra, Fawziah
    [J]. VACCINE, 2011, 29 (48) : 8788 - 8801
  • [5] A Review of DNA Vaccines Against Influenza
    Lee, Leo Yi Yang
    Izzard, Leonard
    Hurt, Aeron C.
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [6] Development of live attenuated influenza vaccines against pandemic influenza strains
    Coelingh, Kathleen L.
    Luke, Catherine J.
    Jin, Hong
    Talaat, Kawsar R.
    [J]. EXPERT REVIEW OF VACCINES, 2014, 13 (07) : 855 - 871
  • [7] Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review
    Mathebula, Lindi
    Ndwandwe, Duduzile Edith
    Pienaar, Elizabeth
    Wiysonge, Charles Shey
    [J]. BMJ OPEN, 2019, 9 (07):
  • [8] Quadrivalent Vaccines for the Immunization of Adults against Influenza: A Systematic Review of Randomized Controlled Trials
    Mannocci, Alice
    Pellacchia, Andrea
    Millevolte, Rossella
    Chiavarini, Manuela
    de Waure, Chiara
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (15)
  • [9] Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases
    V. Baldo
    T. Baldovin
    A. Floreani
    E. Fragapane
    R. Trivello
    [J]. Journal of Clinical Immunology, 2007, 27 : 542 - 547
  • [10] Mismatched influenza vaccines may still be effective
    McCarthy, Jacob
    [J]. FUTURE VIROLOGY, 2013, 8 (08) : 731 - 731